Yu Fan
Long book
$97.0M
Q1 2026
Positions
8
Top-10 weight
100%
concentration
Last quarter
+19.4%
SPY +14.8%
Turnover
38%
of book per quarter
Strategy in plain words
auto-generated from filingsYu Fan is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $97.0M US long book across 8 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: KESTRA MEDICAL TECHNOLOGIES, ALUMIS INC, CERIBELL INC, INVENTIVA SA - ADR, WHITEHAWK THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 7.7pp per quarter behind the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-29.8%
Q2 2024
+12.8%
Q3 2024
-24.2%
Q4 2024
-24.8%
Q1 2025
-22.9%
Q2 2025
+10.7%
Q3 2025
+33.9%
Q4 2025
-4.2%
Q1 2026
+19.4%
Sector allocation
Healthcare 100%
Financials 0%
Long book by quarter
What does Yu Fan own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| KMTS KESTRA MEDICAL TECHNOLOGIES | Healthcare | 2.3M | $45.5M | 46.9% | Held |
| ALMS ALUMIS INC | Healthcare | 776.8K | $17.1M | 17.6% | -1.6% |
| CBLL CERIBELL INC | Healthcare | 549.4K | $10.1M | 10.4% | Held |
| WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 2.1M | $7.1M | 7.4% | Held |
| CATX PERSPECTIVE THERAPEUTICS INC | Healthcare | 1.1M | $4.4M | 4.5% | New |
| PMN PROMIS NEUROSCIENCES INC | Healthcare | 329.8K | $4.2M | 4.3% | New |
| ABTC AMERICAN BITCOIN CORP-A | Financials | 308.1K | $285K | 0.3% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 18, 2026 | 8 | $97.0M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 18, 2026 | 5 | $92.3M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 4 | $76.9M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 5 | $73.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 9 | $97.3M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 7 | $53.2M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 6 | $32.5M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 6 | $76.5M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 5 | $72.5M | canonical | SEC ↗ |